CRESCENT BIOPHARMA, INC.
For the period ended Mar 31, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 29, 2026
CBIO$13.65+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $189,163 | $213,192 |
| Accounts receivable, net | — | 18,000 |
| Prepaid expenses and other current assets | 6,400 | 5,463 |
| Total current assets | 195,563 | 236,655 |
| Property and equipment, net | 929 | 846 |
| Operating lease right-of-use assets | 1,372 | 1,469 |
| Restricted cash | 107 | 107 |
| Other assets | 1,159 | 1,216 |
| Total assets | $199,130 | $240,293 |
| Liabilities, Convertible Preferred Shares, and Shareholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $1,190 | $9,997 |
| Accrued expenses and other current liabilities | 4,433 | 16,344 |
| Related party accounts payable and other current liabilities | — | 140 |
| Deposit liability | 5,000 | 5,000 |
| Deferred revenue | 3,117 | 4,156 |
| Operating lease liability, current | 453 | 435 |
| Total current liabilities | 14,193 | 36,072 |
| Long term liabilities | ||
| Operating lease liability, noncurrent | 1,090 | 1,209 |
| Total liabilities | 15,283 | 37,281 |
| Commitments and contingencies (Note 13) | ||
| Shareholders’ equity: | ||
| Non-voting convertible preferred shares, $0.001 par value; 5,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 2,890 Series A designated shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 4,000 | 4,000 |
| Ordinary shares, $0.001 par value; 175,000,000 shares authorized as of March 31, 2026 and December 31, 2025, 27,571,935 and 27,556,767 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 28 | 28 |
| Additional paid-in capital | 374,911 | 370,793 |
| Accumulated deficit | (195,092) | (171,809) |
| Total shareholders' equity | 183,847 | 203,012 |
| Total liabilities, convertible preferred shares, and shareholders’ equity | $199,130 | $240,293 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.